Medical news and careers, clearly connected
CareZelo
English
Menu

Public health updates

Public healthCanada

Baxter to discontinue 200 mg cyclophosphamide intravenous solution by year end 2026

Baxter Corporation reports its Procytox (cyclophosphamide) 200 mg powder for intravenous solution (DIN 02241797) will be discontinued on Dec 31, 2026, for business reasons. The discontinuation decision will not be reversed.

Cyclophosphamide is a standard chemotherapy drug — cancer care teams should plan the switch to another strength or product before Dec 31.

Discontinuation date: Dec 31, 2026 All deadlines

Ask about this brief

Answers are written by AI from this brief and can be wrong. Check the original source before you act.

2 free questions a day without an account. Members ask as often as they like, free.

Not medical, legal or immigration advice. Questions are kept anonymously to improve our briefs.

Read the original

Official source: Baxter to discontinue 200 mg cyclophosphamide intravenous solution by year end 2026 (opens in a new tab) — Health Product Shortages Canada

Report a problem

Due in 20 daysPublic healthCanada

Accel Pharma reports upcoming two-week shortage of ondansetron 8 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 8 mg (ACCEL-ONDANSETRON ODT, DIN 02535327) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Official source: Health Product Shortages Canada (opens in a new tab)

Due in 20 daysPublic healthCanada

Accel Pharma reports upcoming two-week shortage of ondansetron 4 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 4 mg (ACCEL-ONDANSETRON ODT, DIN 02535319) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Official source: Health Product Shortages Canada (opens in a new tab)

Due in 39 daysPublic healthCanada

Sandoz rabeprazole 20 mg supply disruption expected until early December

Sandoz Canada reports its rabeprazole sodium 20 mg enteric-coated tablet (DIN 02314185) faces an anticipated shortage from Oct 26 to Dec 4, 2026, after a disruption in the manufacture of the drug.

Rabeprazole is a commonly prescribed stomach-acid drug — prescribers and pharmacies should plan alternatives while the shortage is expected.

Official source: Health Product Shortages Canada (opens in a new tab)

Due in 18 daysPublic healthCanada

Sandoz dexamethasone injection supply faces temporary shortage through mid-November

Sandoz Canada reports its dexamethasone sodium phosphate injection 10 mg/mL (DIN 00874582), for intravenous, intramuscular or intrasynovial use, faces an anticipated shortage from Oct 26 to Nov 13, 2026, driven by increased demand.

Dexamethasone injection is a staple steroid in hospitals and clinics — care teams should check stock before the anticipated shortage bites.

Official source: Health Product Shortages Canada (opens in a new tab)